| mRNA |
Crizotinib |
GDSC1000 |
pan-cancer |
AAC |
-0.0046 |
0.9 |
| mRNA |
Sorafenib |
FIMM |
pan-cancer |
AAC |
0.014 |
0.9 |
| mRNA |
TL-2-105 |
GDSC1000 |
pan-cancer |
AAC |
0.0029 |
0.9 |
| mRNA |
LY-2183240 |
CTRPv2 |
pan-cancer |
AAC |
0.0026 |
0.9 |
| mRNA |
BRD-A05715709 |
CTRPv2 |
pan-cancer |
AAC |
-0.0047 |
0.9 |
| mRNA |
ISOX |
CTRPv2 |
pan-cancer |
AAC |
0.0026 |
0.9 |
| mRNA |
decitabine:carboplatin (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0023 |
0.9 |
| mRNA |
erlotinib:PLX-4032 (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0029 |
0.9 |
| mRNA |
HG-5-113-01 |
GDSC1000 |
pan-cancer |
AAC |
0.0036 |
0.9 |
| mRNA |
BRD9876:MK-1775 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0081 |
0.9 |